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ABSTRACT
Endometrial cancer (EC) is one of the most frequent causes of cancer death 
among women in developed countries. Histopathological diagnosis and imaging 
techniques for EC are limited, thus new prognostic markers are needed to offer 
patients the best treatment and follow-up.
In the present paper we showed that the level of mitochondrial ribosomal protein 
MRPS18-2 (S18-2) increased in EC compared with the normal endometrium and 
hyperplasia, based on a study of 42 patient biopsies. Importantly, high expression 
of free E2F1 in EC correlates well with high S18-2 expression. The EC cell line HEC-
1-A, which overexpresses S18-2 constitutively, showed an increased proliferation 
capacity in vitro and in vivo (in SCID mice). Moreover, pan-keratin, beta-catenin and 
E-cadherin signals are diminished in these cells, compared to the parental HEC-1-A 
line, in contrast to vimentin signal that is increased. This may be associated with 
epithelial-mesenchymal cell transition (EMT).
We conclude that high expression of S18-2 and free E2F1, and low pan-keratin, 
beta-catenin, and E-cadherin signals might be a good set of prognostic markers for EC.
INTRODUCTION
Endometrial cancer (EC) accounts for about 6% 
of all cancer in females worldwide and is one of the 
most frequent causes of cancer death among women in 
developed countries. The number of new cases of EC 
has gradually risen since 1960, and EC now accounts for 
40% of gynecological cancers worldwide. Overweight, 
hypertension, physical inactivity, diabetes, and family 
history are among the most important risk factors for 
EC [1].
EC originates in the endometrial lining of the uterus. 
Up to 10% of EC develops into an aggressive form of the 
disease, with 5-year survival rates between 5% and 10% [2]. 
All women with EC who are considered operable undergo 
hysterectomy and bilateral salpingophorectomy. In cases 
with aggressive tumor histology, such as low differentiation 
or aneuploidy, a more extensive procedure is recommended, 
such as pelvic and paraortal lymph node evacuation and 
omentectomy [3]. Current imaging techniques like CT, 
MRI and PET have low sensitivity and specificity to locate 
endometrial tumors and their depth of invasion into the 
myometrium and cervix, or lymph node metastases. Current 
recommendations for surgical treatment are based on the 
histology of the endometrial biopsy. Histopathology does 
not reflect the molecular properties of tumors [4]. Thus, 
the current limitations of histopathological diagnosis and 
imaging techniques of EC require the development of 
biomarkers that reflect the molecular functional profile 
of endometrial tumors. Identification of new prognostic 
markers is important as it will allow us to offer the best 
treatment and follow-up to EC patients [5].
The mitochondrial ribosomal protein S18-
2 (MRPS18-2, NP_054765; S18-2 later in the text) 
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might be considered as one of the possible markers. 
Overexpression of this protein in primary rat fibroblasts 
resulted in immortalization and eventual transformation of 
cells, as we found recently. Immortalized cells showed a 
phenotype resembling that of stem cells [6, 7]. Moreover, 
chromosomal instability was induced in transformed cells, 
which gave rise to tumors in SCID mice [8]. We have also 
shown previously that S18-2 protein binds RB (RB1, 
NP_000312), consequently freeing E2F1 (NP_005216) 
[9, 10]. Thus, it seems clear that overexpression of S18-2 
provides a permanent stimulus for cell division, suggesting 
that it is involved in carcinogenesis.
To explore this, in the present paper we studied 
expression of S18-2 and free E2F1 proteins in EC, 
hyperplasia (HP), and the normal endometrium (NE). 
We also studied the influence of a high S18-2 expression 
on levels of anti-keratin, beta-catenin, E-cadherin, and 
N-cadherin in the EC-derived HEC1-A cell line and sub-
line that expressed S18-2 constitutively at high levels.
RESULTS
Characteristics of patient groups
ECs were graded based on morphological features, 
according to the criteria of the 2009 International 
Federation of Gynecology and Obstetrics (FIGO) [11] 
and placed in six tissue categories: i) highly differentiated 
adenocarcinoma (HDA, FIGO grade 1); ii) moderately 
differentiated adenocarcinoma (MDA, FIGO grade 2); iii) 
minimally differentiated adenocarcinoma (LDA, FIGO 
grade 3); iv) serous cancers (SC); v) HP; and vi) NE.
Some tissue samples contained different histological 
areas, for example, adenocarcinoma and HP, serous tumor 
and HP, etc. Age and body mass index (BMI) distribution 
were studied for all women. Age (Figure S1A) and BMI 
(Figure S1B) did not differ significantly across the six 
groups of patients. Influence of the number of births and 
tumor recurrence were not considered in the present paper.
Expression of progesterone receptor (PR) and 
estrogen receptor (ER, ESR1, NP_000116) was also 
analyzed in tissues. As was expected, PR expression 
tended to decrease with tumor progression (Figure S1C), 
while ER expression was high in all samples of tumor 
tissue (Figure S1D).
Expression of S18-2 protein is increased in 
tumors, compared with normal tissues and 
hyperplasia
S18-2 signal was almost absent in NE samples and 
very weak in HP. In contrast, EC demonstrated a strong 
S18-2 signal in cytoplasm (Figure 1). It is worth noting 
that a proportion of cancerous cells in LDA and SC 
Figure 1: S18-2 protein expression in cancerous and normal cells. S18-2 signal (in brown) is elevated in cancerous cells (red 
arrows) in comparison with stromal cells (green arrows). Highly differentiated tumors are shown A, B. Kruskal–Wallis tests were applied to 
six tissue categories, comprising three endometrioid adenocarcinomas at various differentiation stages and serous carcinoma, hyperplasia, 
and normal endometrium. In all tumors S18-2 is expressed at a significantly higher level than in hyperplasia (HP) or normal endometrium 
(NE) (p<0.05) C. No significant differences (p>0.05) in expression of two types of tumors were observed. Notice the tendency of the S18-2 
signal to decrease in advanced endometrioid adenocarcinomas D.
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showed a nuclear S18-2 signal. However, this proportion 
did not exceed 5% of all tumor cells. An example of S18-2 
staining in EC samples are shown on Figure 1A and 1B.
We observed a significant difference (p<0.05) in 
S18-2 expression in all EC samples and in HP and NE 
samples combined (Figure 1C). Interestingly, S18-2 
expression was high in all tumor tissue categories, but 
LDA tended to show decreased S18-2 expression (Figure 
1D). This expression pattern may be connected to the 
stability of the S18-2 protein, which is largely unknown.
Expression of the free E2F1 is increasing with 
the tumor grade
Due to the fact that S18-2 protein levels were 
elevated in tumor samples, it was of great importance to 
assess expression of the free E2F1 protein. To do so, the 
antibody raised against the C-terminus of E2F1 (residues 
409-426) was used. It was shown that RB protein binds 
the C-terminal portion of E2F1 and this binding abolishes 
the transactivating ability of the latter [12, 13]. The 
signal of the free E2F1 was elevated in less differentiated 
tumors, and it was significantly higher than in NE and 
HP (Figure 2). The high free E2F1 expression in tumors 
correlates well with highly expressed S18-2.
Overexpression of S18-2 in HEC-1-A EC 
cells induces epithelial-mesenchymal cell 
transition (EMT)
As was described above, tumors tissues showed a 
higher S18-2 signal. To find out the molecular changes in 
EC cells, HEC-1-A line produced from EC and its sub-
line that overexpressed ectopical S18-2 (HEC-1-A-S18-2) 
were compared. Levels of S18-2 protein were assessed by 
immunostaining with anti-S18-2 antibody (Figure 3A, 
the top panel). To compare cell properties, expression 
pattern of pan-keratin, cytokeratin 18, E-cadherin, 
N-cadherin, beta-catenin, and vimentin was studied by 
immunofluorescent analysis. The decrease in the signals of 
pan-keratin, cytokeratin 18, beta-catenin, and E-cadherin 
and increase of vimentin signal was observed in the HEC-
1-A-S18-2 cells that expressed S18-2 constitutively at the 
high level, as compared with the parental cells (Figures 
3 and 4). Levels of N-cadherin were either unchanged or 
decreased in HEC-1-A-S18-2 cells (Figure 3B). Contrary, 
vimentin was stained only in HEC-1-A-S18-2 cells 
(Figure 4A and 4B). Noteworthy, the latter showed more 
“fibroblast-like” morphology (Figure 4A and 4B). This 
suggests that cells undergo EMT upon overexpression 
of S18-2, which is usually associated with an enhanced 
Figure 2: Free E2F1 expression in cancerous and normal cells. Kruskal–Wallis tests were applied to six groups, comprising 
three of endometrioid adenocarcinomas at various differentiation stages and serous carcinoma, hyperplasia, and normal endometrium. In 
all tumors E2F1 showed a significantly higher signal than in hyperplasia or normal endometrium (p<0.05) A. Notice that the nuclear E2F1 
signal was lower in more differentiated tumors, HDA B, C. compared with more advanced tumor, MDA D.
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invasion ability of tumor cells. The proliferation capacity 
was assessed for both, parental HEC-1-A cells and the 
sub-line that expresses S18-2 constitutively at the high 
levels. Increase in relative proliferation was detected in 
HEC-1-A-S18-2 cells (Figure 4D).
Expression of S18-2 in HEC-1-A cells increases 
the rate of tumor growth in SCID mice
Based on the immunochemistry experiments and 
in order to characterize the tumorigenicity of the HEC-
1-A and the HEC-1-A-S18-2 cell line, cells were injected 
subcutaneously into SCID mice. Tumors were found in 
100% (8 spots out of 8 injections) of the experimental 
animals and were detected 1-2 weeks after inoculation. All 
experimental animals were sacrificed at the same time on 
day 23, when the largest tumor reached 1 cm3, as stated in 
a protocol and approved by the Ethical committee. After 
analysis of growth curves, we concluded that the HEC-
1-A-S18-2 cell line proliferated faster than the primary 
HEC-1-A cells (Figure 5A).
HEC-1-A cells, as expected, gave rise to well 
differentiated endometrioid carcinomas in experimental 
animals (Figure 5B, the top panel). Gland-like structures 
(indicated by black arrows) and necrotic areas (green 
arrows) appeared in tumors that developed in just 3 weeks. 
When HEC-1-A-S18-2 cells proliferated in SCID mice, 
the resultant tumors showed similar features, i.e., areas of 
necrosis and gland-like structures (Figure 5B, the bottom 
panel). However, these tumors were different in that they 
had a large number of blood vessels and more isolated 
gland-like structures, forming foci (indicated by arrows). 
To the naked eye, such tumors looked more differentiated 
than those obtained by inoculation of parental HEC-1-A 
cells.
DISCUSSION
EC is divided into two types. Type 1 EC is 
morphologically classified as endometrioid carcinoma. It 
accounts for 80% of all cases and affects both pre- and 
post-menopausal women. Type 2 EC is morphologically 
classified as serous or clear cell carcinoma and affects 
older, postmenopausal women. Type 2 EC develops 
directly from the endometrium without hyperplasia. 
These tumors are often poorly differentiated and have 
a worse prognosis. Type 1 EC is characterized by a 
variety of genetic alterations, the most frequent of 
which are mutations in the tumor suppressor gene PTEN 
(NM_000314). PTEN mutations have been observed 
in up to 83% of endometrioid carcinomas and 55% of 
precancerous endometrial lesions [14–16].
Figure 3: Expression pattern of S18-2, beta-catenin, pan-keratin, cytokeratin 18, E- and N-cadherins in HEC-1-
A-S18-2 cells compared with HEC-1-A. Notice the strong signal of ectopic S18-2 in HEC-1-A-S18-2 cells, compared to endogenous 
signal in original cell line (green on the merged images, white when single). Notice the dramatic reduction of beta-catenin, pan-keratin and 
cytokeratin 18 expression in HEC-1-A-S18-2 cells. DNA is shown in blue A. Notice the significant reduction of E-cadherin expression in 
HEC-1-A-S18-2 cells, compared to original cell line (green on the merged images, white when single). DNA is shown in blue on the merged 
images and white when alone B. Images were taken with objective x63.
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The high TP53 (NP_000537) expression is a good 
prognostic marker for type 1 EC, it is higher in grade 3 
than grade 1 tumors or NE tissue [17, 18]. The TP53 is 
mutated in only 10 to 15% of EC [19]. Earlier we showed 
that high TP53 expression is inversely correlated with 
MDM2 (NP_001138809) expression, which suggests that 
TP53 is not functional in endometrioid adenocarcinomas 
[20]. Although the mechanism of this stabilization has not 
yet been revealed, it may be linked to the high level of ER 
in endometrioid adenocarcinoma.
Contrary to type 1 EC, TP53 is mutated in about 
90% of type 2 EC, such as serous carcinoma. Other 
frequent genetic alterations in type 2 EC are inactivation 
of p16 (CDKN2A, NP_000068) and overexpression of 
HER-2/neu (CD340, ERBB2, NP_001005862) [21–23]. 
The p16 tumor suppressor gene encodes the CDK inhibitor 
that is involved in the phosphorylation of RB protein, 
i.e in regulation of the RB-E2F pathway [24–26]. Thus, 
inactivation of p16 leads to uncontrolled cell growth.
The best prognostic markers for endometrioid 
carcinoma (type 1 EC) are the high levels of the TP53, 
ER, and PTEN mutations. Other genetic alterations in 
endometrioid carcinoma include microsatellite instability 
and specific mutations of K-RAS and β-catenin genes. 
β-catenin, a component of the E-cadherin unit of proteins, 
is essential for cell differentiation, the maintenance of 
Figure 4: Pattern of vimentin expression and proliferation of HEC-1-A-S18-2 cells compared with HEC-1-A. Signals 
of vimentin (green) and DNA (blue) were overlaid with the phase contrast (grey). Images were taken with objective x63. Notice the 
fibroblast-like morphology of HEC-1-A-S18-2 cells (indicated by arrows) A, B. and elevated vimentin signal in them (A, B) compared with 
parental HEC-1-A cells C. Notice the increased proliferation of HEC-1-A-S18-2 cells compared to parental HEC-1-A cells D. It is shown 
by percentage of increase in intensity of fluorescent signal that is proportional to cell number. The experimental value for HEC-1-A cells 
was taken as 100%. Experiments were performed for 500, 1000 and 3000 cells for each cell line in triplicates. Here the mean values and 
standard deviations are shown.
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normal tissue architecture, and plays an important role 
in signal transduction [27–29]. Furthermore, E-cadherin 
expression occurs in only 62% and 87% of serous and 
clear cell cancers, respectively. Decreased E-cadherin 
expression is associated with a loss in cell-cell cohesive 
forces. E-cadherin-negative tumors are associated with 
poorer prognosis [30, 31].
In our study, expression of S18-2 and free E2F1 
proteins increased significantly in tumor tissue compared 
to NE an HP samples. This correlates with the fact that 
S18-2 competes with RB protein for E2F1 binding, 
thus abolishes hinders in the S-phase entry [10]. As 
was mentioned in the introduction, overexpression of 
S18-2 in primary rat cells led to their immortalization 
and transformation. We have also previously reported 
that ectopic expression of S18-2 in tumor cell lines, 
such as breast cancer cell line MCF7 and kidney tumor 
cells KRC/Y, led to a disturbance in the cell cycle and 
the formation of multinucleated cells [32]. Interesting 
question is whether the cytoplasmic and nuclear S18-2 
might perform different functions or not. Probably, nuclear 
S18-2 could be a sign for the worse prognosis, but this 
needs the further investigation.
The EC HEC-1-A cell line, which overexpresses 
S18-2 constitutively, showed increased proliferation 
capacity in vitro and in vivo (in SCID mice). Moreover, 
pan-keratin, beta-catenin and E-cadherin signals were 
diminished in these cells, compared to the parental HEC-
Figure 5: Proliferation of cells that were inoculated into SCID mice subcutaneously. Notice that HEC-1-A-S18-2 cells 
produced larger tumors than parental HEC-1-A cells A. When HEC-1-A cells were introduced into SCID mice (the top panel), necrotic area 
(indicated by green arrows) and also well developed gland-like structures (black arrows) was developed. When HEC-1-A-S18-2 cells were 
inoculated, they formed more nicely formed foci (indicated by arrows) B.
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1-A line, suggesting that S18-2 promotes epithelial-
mesenchymal cell transition (EMT). Increased vimentin 
signal in HEC-1-A-S18-2 cells, compared with parental 
line, allows us to draw the same conclusion. Studies on 
larger number of cell lines are needed to support an idea 
that the highly expressed S18-2 might be a “surrogate 
marker” for EMT.
MATERIALS AND METHODS
Endometrial tissue samples
Samples were collected from 42 patients with 
endometrial cancer who underwent surgery at the 
Department of Women’s and Children’s Health, 
Karolinska University Hospital (Stockholm, Sweden). 
Two separate biopsies were taken from each patient: 
one from the endometrial tumor tissue and one from the 
normal endometrium (n=84 samples). In addition, some 
samples of NE and HP (10 samples of each) were collected 
by scraping the uterus mucosa. Biopsies were fixed in a 
neutral buffered 4% formaldehyde solution. After fixation, 
dehydration, and embedding in paraffin, serial sections 
were cut at a normal thickness of 5 μm and stained with 
hematoxylin/eosin for histological diagnosis.
Endometrial adenocarcinomas were graded based 
on morphological features, according to the criteria of 
the 2009 International Federation of Gynecology and 
Obstetrics (FIGO) [11] and placed in six tissue categories: 
i) highly differentiated adenocarcinoma (HDA, FIGO 
grade 1); ii) moderately differentiated adenocarcinoma 
(MDA, FIGO grade 2); iii) minimally differentiated 
adenocarcinoma (LDA, FIGO grade 3); iv) serous cancers 
(SC); v) HP; and vi) normal endometrium (NE).
Antibodies and immunohistochemistry
S18-2 and free E2F1 protein expression was 
determined by immunohistochemistry of the paraffin-
embedded tissue sections. Paraffin was dissolved in xylol 
and the tissue rehydrated by stepwise washing with EtOH 
in phosphate-buffered saline (PBS) (99%, 90%, 70%, and 
30% EtOH). Tissues were then treated in a 2% solution 
of H2O2 in methanol at room temperature for 30 min to 
reduce background staining. Epitopes were exposed by 
hot citrate buffer (water bath, 92°C for 15 min). Rabbit 
polyclonal anti-S18-2 (Proteintech Group, Inc., Chicago, 
IL, USA) and mouse monoclonal anti-E2F1 (clone 2E10, 
Sigma-Aldrich, St. Louis, MO, USA) antibodies were 
diluted (1:200) in blocking buffer (2% bovine serum 
albumin, 0.2% Tween-20, 10% glycerol, and 0.05% NaN3 
in PBS). To stain for free E2F1, the mouse monoclonal 
antibody raised against the C-terminus of protein was 
used. It is known that the C-terminal portion of E2F1 
(residues 409-426) is involved in binding with RB protein, 
and therefore in the regulation of the transactivating ability 
of E2F1 [12, 13]. Protein signals were visualized with 
the help of the EnVision™ Detection Peroxidase/DAB 
system (Dako, Glostrup, Denmark). Nuclei were stained 
with hematoxylin (Dako). Staining was evaluated using 
a semi-quantitative method, i.e., the number of cells that 
showed signal was counted. The minimum number of 
tumor (normal) cells counted was 900.
Cell culture and immunostaining
The HEC-1-A cell line (ATCC HTB-112) was 
purchased from ATCC biological resource center 
(Manassas, VA, USA). This endometrial cell line was 
isolated from a patient with stage IA EC as described 
previously [33].
All cell lines were cultured in Iscove’s medium, 
which contained 10% fetal bovine serum and appropriate 
antibiotics, at 37°C.
The HEC-1-A (1–2·104) cells were transfected 
with either a plasmid that encodes GFP-fused S18-2 
(GFP-S18-2) protein as described previously [10], or with 
a vector, using Lipofectamine 2000 (Life Technologies, 
Carlsbad, CA, USA). GFP-plasmid was chosen to 
achieve the high ectopic expression of S18-2. After 3 
weeks in Iscove’s medium that contained 0.5 mg/ml 
G418, transfected cells (clones) were selected. From a 
7.5-cm-diameter Petri dish, 6 clones were collected and 
cultured in six-well plates. Two clones (designated as 
HEC-1-A-S18-2 in the text) that expressed the highest 
level of GFP-S18-2 were selected for further experiments. 
Before immunostaining, cells were grown on cover slips 
in six-well plates. Cells were fixed in a mixture of cold 
methanol and acetone (1:1) at –20°C, and prior staining 
they were rehydrated in PBS. Rabbit anti-S18-2 and 
anti-beta catenin antibodies (Sigma-Aldrich) and mouse 
monoclonal anti-E-cadherin, N-cadherin (Cell Signaling 
Technology, Danvers, MA, USA), anti-keratin and Pan 
Ab-1 (Thermo Scientific, Waltham, MA, USA), and anti-
vimentin (Dako) antibodies were used. Mouse monoclonal 
anti-cytokeratin 18 was the kind gift of Svitlana Sidorenko 
(IEPOR of NASU, Kyiv, Ukraine). Rabbit anti-mouse 
and swine anti-rabbit FITC-conjugated (Dako) sera were 
used as secondary antibodies. Hoechst 33258 (Sigma-
Aldrich) was added at a concentration of 0.4 µg/mL to 
the secondary antibody for DNA staining. Staining images 
were captured using a DAS microscope Leitz DM RB 
with a dual-mode cooled charge-coupled device camera 
(C4880; Hamamatsu, Japan). Photoshop and Image J 
software were used to assemble overlay images.
Cell proliferation assay
Relative proliferation of cells was studied, using 
the CyQUANT®NF assay (Invitrogen, Carlsbad, CA, 
USA). Briefly, 500, 1000 and 3000 cells of HEC-1-A and 
HEC-1-A-S18-2 were grown in triplicates in a 96 well 
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plate overnight in IMDM medium. After medium was 
removed, an aliquot of fluorescent dye was added and cells 
were incubated for 60 min at 37ºC. After incubation, the 
fluorescence intensity was measured at λ=530 nm, using 
microplate reader Omega (BMG Labtech, Ortenberg, 
Germany). Percentage proliferation was calculated for 
HEC-1-A-S18-2 in comparison with control cells HEC-
1-A, taken as 100%.
Inoculation of cells in experimental animals, 
SCID mice
EC HEC-1-A-S18-2 and parental HEC-1-A cells 
(3×106 cells) were then introduced into the left and right 
sides of SCID mice; four SCID mice were used for each 
cell line. All experimental animals were sacrificed at the 
day 23, when the largest tumor reached 1 cm3, as stated in 
a protocol and approved by the Ethical committee.
Ethical approvals
Tissue sampling was approved by the Ethics 
Committee of Karolinska Institutet/Karolinska University 
Hospital (permit 2006/649), and all women gave written 
informed consent. Ethical permission to induce tumors in 
mouse models has also been obtained and is valid for 5 
years (Solna court decision number 192/14 from October 
9th, 2014).
Statistical analysis
GraphPad Prism software (version 6, GraphPad 
Software, La Jolla, CA, USA) was used for multiple 
comparisons of nonparametric criteria. The means of the 
S18-2 and E2F1 expression (as a percent of positive cells) 
were analyzed. Further analysis was performed on the 
combined mean of each set of tumors, according to their 
grade. A detailed description of the calculations is given 
in the figure legends.
CONCLUSIONS
Taken together, our data suggest that a combination 
of high S18-2 and free E2F1 expression, in parallel with 
decreased expression of beta-catenin, pan-keratin, and 
E-cadherin, may be a good set of prognostic markers for EC.
CONFLICTS OF INTEREST
Authors declare no competing interests.
GRANT SUPPORT
This work was supported by Concern Foundation 
(Los Angeles) and the Cancer Research Institute 
(New York), the Swedish Institute, the regional agreement 
on medical training and clinical research (ALF) between 
Stockholm County Council and Karolinska Institutet 
(number 541150), the Swedish Labor Market Insurance, 
and by the research program 2.2.5.384 of National 
Academy of Science of Ukraine.
REFERENCES
1. Prat J, Gallardo A, Cuatrecasas M, Catasus L. 
Endometrial carcinoma: pathology and genetics. Pathology. 
2007; 39: 72-87. doi: 10.1080/00313020601136153.
2. Mhawech-Fauceglia P, Wang D, Kesterson J, Clark K, 
Monhollen L, Odunsi K, Lele S, Liu S. Microarray analysis 
reveals distinct gene expression profiles among different 
tumor histology, stage and disease outcomes in endometrial 
adenocarcinoma. PLoS One 2010; 5: e15415. doi: 10.1371/
journal.pone.0015415.s001.
3. May K, Bryant A, Dickinson HO, Kehoe S, Morrison J. 
Lymphadenectomy for the management of endometrial 
cancer. Cochrane Database Syst Rev 2010; 1: CD007585. 
doi: 10.1002/14651858.CD007585.pub2.
4. Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, 
Stefansson IM, Raeder MB, Sos ML, Engelsen IB, Trovik 
J, Wik E, Greulich H, Bo TH, et al. Integrated genomic 
profiling of endometrial carcinoma associates aggressive 
tumors with indicators of PI3 kinase activation. Proc Natl 
Acad Sci U S A 2009; 106: 4834-4839. doi: 10.1073/
pnas.0806514106.
5. Mannelqvist M, Stefansson I, Salvesen HB, Akslen LA. 
Importance of tumour cell invasion in blood and lymphatic 
vasculature among patients with endometrial carcinoma. 
Histopathology 2009; 54: 174-183. doi: 10.1111/j.1365-
2559.2008.03201.x HIS3201 [pii].
6. Kashuba E, Yenamandra SP, Darekar SD, Yurchenko 
M, Kashuba V, Klein G, Szekely L. MRPS18-2 protein 
immortalizes primary rat embryonic fibroblasts and 
endows them with stem cell-like properties. Proc Natl 
Acad Sci U S A 2009; 106: 19866-19871. doi: 10.1073/
pnas.0911545106 0911545106 [pii].
7. Yenamandra SP, Darekar SD, Kashuba V, Matskova L, Klein 
G, Kashuba E. Stem cell gene expression in MRPS18-2-
immortalized rat embryonic fibroblasts. Cell Death Dis 2012; 
3: e357. doi: 10.1038/cddis.2011.138 cddis2011138 [pii].
8. Darekar SD, Mushtaq M, Gurrapu S, Kovalevska L, 
Drummond C, Petruchek M, Tirinato L, Di Fabrizio E, 
Carbone E, Kashuba E. Mitochondrial ribosomal protein 
S18-2 evokes chromosomal instability and transforms 
primary rat skin fibroblasts. Oncotarget 2015; 6: 21016-
21028. doi: 10.18632/oncotarget.4123.
9. Snopok B, Yurchenko M, Szekely L, Klein G, Kashuba 
E. SPR-based immunocapture approach to creating an 
interfacial sensing architecture: Mapping of the MRS18-2 
binding site on retinoblastoma protein. Analytical and 
bioanalytical chemistry 2006; 386: 2063-2073. doi: 
10.1007/s00216-006-0867-6.
Oncotarget22158www.impactjournals.com/oncotarget
10. Kashuba E, Yurchenko M, Yenamandra SP, Snopok 
B, Isaguliants M, Szekely L, Klein G. EBV-encoded 
EBNA-6 binds and targets MRS18-2 to the nucleus, 
resulting in the disruption of pRb-E2F1 complexes. Proc 
Natl Acad Sci U S A 2008; 105: 5489-5494. doi: 10.1073/
pnas.0801053105 0801053105 [pii].
11. Mutch DG. The new FIGO staging system for cancers 
of the vulva, cervix, endometrium and sarcomas. 
Gynecologic Oncology 2009; 115: 325-328. doi: 10.1016/j.
ygyno.2009.10.050.
12. Helin K, Harlow E, Fattaey A. Inhibition of E2F-1 
transactivation by direct binding of the retinoblastoma 
protein. Mol Cell Biol 1993; 13: 6501-6508.
13. Zaragoza K, Begay V, Schuetz A, Heinemann U, Leutz A. 
Repression of transcriptional activity of C/EBPalpha by 
E2F-dimerization partner complexes. Mol Cell Biol 2010; 
30: 2293-2304. Doi: 10.1128/MCB.01619-09 MCB.01619-
09 [pii].
14. Prat J. Prognostic parameters of endometrial carcinoma. 
Hum Pathol 2004; 35: 649-662. doi: S0046817704001352 
[pii].
15. Matias-Guiu X, Prat J. Molecular pathology of endometrial 
carcinoma. Histopathology 2013; 62: 111-123. doi: 10.1111/
his.12053.
16. Yin Y, Shen WH. PTEN: a new guardian of the genome. 
Oncogene 2008; 27: 5443-5453. doi: 10.1038/onc.2008.241 
onc2008241 [pii].
17. Werner HM, Salvesen HB. Current status of molecular 
biomarkers in endometrial cancer. Curr Oncol Rep 2014; 
16: 403. doi: 10.1007/s11912-014-0403-3.
18. Matias-Guiu X, Davidson B. Prognostic biomarkers in 
endometrial and ovarian carcinoma. Virchows Arch 2014; 
464: 315-331. doi: 10.1007/s00428-013-1509-y.
19. Koul A, Willen R, Bendahl PO, Nilbert M, Borg A. Distinct 
sets of gene alterations in endometrial carcinoma implicate 
alternate modes of tumorigenesis. Cancer 2002; 94: 2369-
2379. doi: 10.1002/cncr.10498.
20. Buchynska LG, Nesina IP, Kashuba EV. Different trends 
of p53, MDM2 and p14 ARF expression patterns in 
endometrial adenocarcinomas versus hyperplasia. Exp 
Oncol 2007; 29: 287-294. doi: 33/649 [pii].
21. Lax SF. Molecular genetic pathways in various types of 
endometrial carcinoma: from a phenotypical to a molecular-
based classification. Virchows Arch 2004; 444: 213-223. 
doi: 10.1007/s00428-003-0947-3.
22. Samarnthai N, Hall K, Yeh IT. Molecular profiling of 
endometrial malignancies. Obstet Gynecol Int 2010; 2010: 
162363. doi: 10.1155/2010/162363.
23. Fadare O, Zheng W. Insights into endometrial serous 
carcinogenesis and progression. Int J Clin Exp Pathol 2009; 
2: 411-432.
24. Johnson DG, Degregori J. Putting the Oncogenic and 
Tumor Suppressive Activities of E2F into Context. Curr 
Mol Med 2006; 6: 731-738.
25. Witkiewicz AK, Knudsen KE, Dicker AP, Knudsen ES. 
The meaning of p16(ink4a) expression in tumors: functional 
significance, clinical associations and future developments. 
Cell Cycle 2011; 10: 2497-2503. doi: 16776 [pii].
26. Chandler H, Peters G: Stressing the cell cycle in senescence 
and aging. Curr Opin Cell Biol 2013; 25: 765-771. doi: 
10.1016/j.ceb.2013.07.005 S0955-0674(13)00119-1 [pii].
27. Perez-Moreno M, Fuchs E. Catenins: keeping cells 
from getting their signals crossed. Dev Cell 2006; 11: 
601-612. doi: S1534-5807(06)00462-X [pii] 10.1016/j.
devcel.2006.10.010.
28. Bondow BJ, Faber ML, Wojta KJ, Walker EM, Battle 
MA. E-cadherin is required for intestinal morphogenesis 
in the mouse. Dev Biol 2012; 371: 1-12. doi: 10.1016/j.
ydbio.2012.06.005 S0012-1606(12)00314-4 [pii].
29. Kiewisz J, Wasniewski T, Kmiec Z. Participation of WNT and 
beta-Catenin in Physiological and Pathological Endometrial 
Changes: Association with Angiogenesis. Biomed Res Int 
2015; 2015: 854056. doi: 10.1155/2015/854056.
30. Bacic B, Haller H, Mrklic I, Kosta V, Caric A, Tomic S. 
Prognostic role of E-cadherin in patients with advanced 
serous ovarian cancer. Arch Gynecol Obstet 2013; 287: 
1219-1224. doi: 10.1007/s00404-012-2684-9.
31. Bae YK, Choi JE, Kang SH, Lee SJ. Epithelial-Mesenchymal 
Transition Phenotype Is Associated with Clinicopathological 
Factors That Indicate Aggressive Biological Behavior and 
Poor Clinical Outcomes in Invasive Breast Cancer. J Breast 
Cancer 2015; 18: 256-263. doi: 10.4048/jbc.2015.18.3.256.
32. Shevchuk Z, Yurchenko MY, Darekar SD, Holodnuka-
Kholodnyuk I, Kashuba VI, Kashuba EV. Overexpression 
of MRPS18-2 in Cancer Cell Lines Results in Appearance 
of Multinucleated Cells. Acta Naturae 2013; 5: 85-89.
33. Kuramoto H. Studies of the growth and cytogenetic 
properties of human endometrial adenocarcinoma in culture 
and its development into an established line. Acta Obstet 
Gynaecol Jpn 1972; 19: 47-58.
